Hormonal Management of Endometriosis‑Related Pain

First‑Line Hormonal Therapy

Combined oral contraceptives (COCs) and progestin‑only regimens (including oral or depot medroxyprogesterone acetate) provide comparable pain relief to more expensive GnRH‑agonist protocols and are considered effective first‑line options for dysmenorrhea, non‑cyclical pelvic pain, and dyspareunia in women with endometriosis. Level B evidence supports this equivalence. 1
Progestins, oral contraceptives, and depot medroxyprogesterone acetate each demonstrate statistically significant improvement in pain scores compared with placebo in randomized trials. 1
Initial therapy should be individualized: either a continuous/extended‑cycle COC regimen or a progestin‑only pill (e.g., norethindrone acetate or dienogest) may be started according to contraceptive needs and patient preference. 1

In cases of severe endometriosis, medical therapy alone may be insufficient, necessitating escalation to second‑line agents. 1
If COCs or progestins do not achieve adequate symptom control after a 3–6‑month trial, a GnRH agonist administered for at least 3 months is recommended; its efficacy is comparable to a 6‑month course of danazol. 1
Adding “add‑back” low‑dose estrogen/progestin therapy to GnRH agonists mitigates bone mineral density loss without compromising analgesic effectiveness. 1

No current medical therapy has been shown to eradicate endometriotic lesions. 1
Hormonal treatment does not adversely affect future fertility potential in women with endometriosis. 1
Surgical excision yields marked pain reduction during the first 6 months post‑operatively; however, recurrence of symptoms occurs in up to 44 % of patients within one year. 1

For patients who are asymptomatic, a watch‑and‑wait approach may be appropriate because disease activity can be unpredictable and may regress spontaneously. 1

Breakthrough bleeding usually resolves after the first 21 days of continuous combined oral contraceptive therapy; if bleeding persists, a short 3–4 day hormone‑free interval may be used no more than once per month to preserve efficacy (MMWR Recommendations and Reports, 2024) 2.

Blood pressure must be measured before initiating COCs because uncontrolled hypertension or hypertension with end‑organ complications contraindicates estrogen‑containing contraception (Annales d’endocrinologie, 2012) 3.
Smoking is an absolute contraindication for COCs in women ≥ 35 years old, especially when the daily consumption exceeds 15 cigarettes (Annales d’endocrinologie, 2012) 3.
Estrogen‑containing COCs are contraindicated in patients with diabetes that has vascular complications, a history of venous thromboembolism, migraine with aura, or established cardiovascular disease (Annales d’endocrinologie, 2012) 3.

If any of the above contraindications are present, the recommendation should shift to progestin‑only options such as norethindrone acetate 5 mg daily or a levonorgestrel‑releasing intrauterine device (52 mg) (Annales d’endocrinologie, 2012) 3.
Progestin‑only pills (e.g., norethindrone acetate or dienogest) and the levonorgestrel‑releasing IUD provide pain relief and bleeding control comparable to combined oral contraceptives while avoiding estrogen‑related risks (Annales d’endocrinologie, 2012) 3.
These progestin‑only alternatives are especially appropriate for patients who have estrogen contraindications or who develop intolerable estrogen‑related side effects (Annales d’endocrinologie, 2012) 3.